- Home
- CRNT vs AARD Comparison
CRNT vs AARD Comparison
Compare CRNT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNT
- AARD
- Stock Information
- Founded
- CRNT 1996
- AARD 2017
- Country
- CRNT Israel
- AARD United States
- Employees
- CRNT N/A
- AARD N/A
- Industry
- CRNT Radio And Television Broadcasting And Communications Equipment
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- CRNT Technology
- AARD Health Care
- Exchange
- CRNT Nasdaq
- AARD Nasdaq
- Market Cap
- CRNT 218.8M
- AARD 186.3M
- IPO Year
- CRNT 2000
- AARD 2025
- Fundamental
- Price
- CRNT $2.42
- AARD $17.13
- Analyst Decision
- CRNT Strong Buy
- AARD Strong Buy
- Analyst Count
- CRNT 4
- AARD 7
- Target Price
- CRNT $5.50
- AARD $31.43
- AVG Volume (30 Days)
- CRNT 776.5K
- AARD 208.7K
- Earning Date
- CRNT 11-12-2025
- AARD 11-14-2025
- Dividend Yield
- CRNT N/A
- AARD N/A
- EPS Growth
- CRNT 34.68
- AARD N/A
- EPS
- CRNT 0.15
- AARD N/A
- Revenue
- CRNT $380,518,000.00
- AARD N/A
- Revenue This Year
- CRNT N/A
- AARD N/A
- Revenue Next Year
- CRNT $7.47
- AARD N/A
- P/E Ratio
- CRNT $16.20
- AARD N/A
- Revenue Growth
- CRNT 5.06
- AARD N/A
- 52 Week Low
- CRNT $1.82
- AARD $4.88
- 52 Week High
- CRNT $5.73
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- CRNT 59.11
- AARD 80.00
- Support Level
- CRNT $2.25
- AARD $10.75
- Resistance Level
- CRNT $2.49
- AARD $17.88
- Average True Range (ATR)
- CRNT 0.10
- AARD 1.10
- MACD
- CRNT 0.00
- AARD 0.58
- Stochastic Oscillator
- CRNT 54.47
- AARD 89.62
About CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.